Cytokinetics (CYTK) Research & Development (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Research & Development of $95.5 million for Q1 2026, down 2.79% year-over-year from $98.3 million in Q1 2025, and down 8.5% quarter-over-quarter from $104.4 million in Q4 2025.
Cytokinetics (CYTK) Research & Development (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Research & Development for 17 consecutive years, with $95.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 2.79% year-over-year to $95.5 million; the TTM figure through Mar 2026 stood at $411.7 million (up 15.62% YoY), while the FY2025 annual figure was $416.0 million, up 22.57% from the prior year.
- Research & Development slipped to $95.5 million in Q1 2026 per CYTK's latest filing, from $104.4 million in the prior quarter.
- Across five years, Research & Development topped out at $112.6 million in Q2 2025 and bottomed at $45.9 million in Q1 2022.
- Historically, Research & Development has averaged $83.5 million across 5 years, with a median of $83.2 million in 2023.
- Annual changes were most pronounced in 2023 — Research & Development soared 72.9% — and 2024, when it decreased 4.32%.
- Cytokinetics' Research & Development stood at $75.0 million in 2022, then climbed by 13.27% to $85.0 million in 2023, then gained by 10.18% to $93.6 million in 2024, then climbed by 11.5% to $104.4 million in 2025, then fell by 8.5% to $95.5 million in 2026.
- Business Quant data shows CYTK's Research & Development at $95.5 million in Q1 2026, $104.4 million in Q4 2025, and $99.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 97.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.81 Mn |
| Mar 31, 2026 | 95.53 Mn |
| Dec 31, 2025 | 104.40 Mn |
| Sep 30, 2025 | 99.23 Mn |
| Jun 30, 2025 | 112.55 Mn |
| Mar 31, 2025 | 98.26 Mn |
| Dec 31, 2024 | 93.63 Mn |
| Sep 30, 2024 | 84.61 Mn |
| Jun 30, 2024 | 79.60 Mn |
| Mar 31, 2024 | 81.57 Mn |
| Dec 31, 2023 | 84.98 Mn |
| Sep 30, 2023 | 82.53 Mn |
| Jun 30, 2023 | 83.19 Mn |
| Mar 31, 2023 | 79.42 Mn |
| Dec 31, 2022 | 75.02 Mn |
| Sep 30, 2022 | 62.73 Mn |
| Jun 30, 2022 | 57.13 Mn |
| Mar 31, 2022 | 45.94 Mn |
| Dec 31, 2021 | 43.50 Mn |
| Sep 30, 2021 | 48.44 Mn |